Navigation Links
Cyberonics Announces FDA Approval of Re-Designed AspireHC™ Generator for VNS Therapy
Date:1/3/2012

HOUSTON, Jan. 3, 2012 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX) today announced that the United States Food and Drug Administration (FDA) has approved its re-designed AspireHC (High Capacity) generator, which was the subject of a voluntary product withdrawal in August 2011.

"We are pleased that the FDA was able to complete its review in approximately 60 days, enabling us to resume our limited commercial release of the AspireHC generator in the United States," said Dan Moore, Cyberonics' President and Chief Executive Officer.  "With the CE Mark approval announced in December and a recently obtained Canadian approval, we will also resume the limited commercial release in Europe and initiate a limited commercial release in Canada.  The AspireHC generator addresses a need among some patients for a device with a higher capacity battery and also provides a platform for the AspireSR™ seizure response generator, which is the subject of our E-36 clinical trial in Europe.  We anticipate submission of the re-designed AspireSR generator for ethics committee and competent authority approvals for the E-36 clinical trial no later than the end of our fiscal year in April 2012."

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words.  Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable.  We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning making filings to support the resumption of the AspireSR™ generator E-36 European clinical trial by the end of the fiscal year and resumption of the E-36 clinical trial.  Our actual results may differ materially.  Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy™ and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy™ for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC).  For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 29, 2011, and our Quarterly Report on Form 10-Q for the fiscal quarters ended July 29, 2011 and October 28, 2011.

CONTACT INFORMATION:

Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Main:  (281) 228-7262
Fax:  (281) 218-9332
ir@cyberonics.com


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Receives FDA Approval for Expansion of MRI Use With VNS Therapy® Systems
2. Cyberonics Announces Resignation of James A. Reinstein, Senior Vice President & Chief Commercial Officer
3. Cyberonics Announces Investment in ImThera Medical
4. Cyberonics to Participate in 2011 UBS Global Life Sciences Conference
5. Cyberonics Reports Fiscal 2012 First Quarter Results
6. Cyberonics to Report Fiscal Year 2012 First Quarter Results and Host Conference Call on August 25, 2011
7. Cyberonics Reports Record Fiscal 2011 Results and Provides Fiscal 2012 Guidance
8. Cyberonics to Participate in 2011 Jefferies Global Healthcare Conference
9. Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance
10. Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011
11. Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; ... Favor of God; Second Edition” is the creation of published author, Brooks Rathell. , ... opportunity to talk to you about the financial favor of God. Not only does ...
(Date:9/20/2017)... ... ... “Monique”: is the story of Monique, whose mother’s deteriorating physical condition forces the ... has owned four beauty salons and written a book regarding the author’s success in ... , “The doctor’s office was only three blocks away, and she could walk it, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were selected to receive ... Ross A. Clevens, MD, FACS . The founder and medical director of Clevens ... who trained at Yale, Harvard and the University of Michigan. He has served patients ...
(Date:9/19/2017)... ... September 19, 2017 , ... PAPA Healthcare, Inc. announced ... called, “PAPA Healthcare helps fill gaps, provide essential insights, and improve productivity.” ... operations by leveraging PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s ...
(Date:9/19/2017)... ... September 19, 2017 , ... Peter Chandonait, ... President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project , has ... , The Innovation to Action Award, a USAID Catalyst Award, recognizes USAID staff ...
Breaking Medicine News(10 mins):